Papadimos T J, Escamilla J, Batchelor R A, Lane E W, Biddle J W
Laboratory Medicine Department, Naval Hospital, San Diego, California.
Sex Transm Dis. 1988 Oct-Dec;15(4):196-9. doi: 10.1097/00007435-198810000-00004.
Neisseria gonorrhoeae isolates were studied to determine their patterns of antimicrobial susceptibility and possible chemotherapeutic implications. Of 370 consecutive isolates, 32 (8.7%) were penicillinase-producing N. gonorrhoeae (PPNG). The remaining 338 were subjected to disk-diffusion tests, and those apparently resistant to penicillin, tetracycline, or spectinomycin were tested by an agar-dilution method. The dilution test showed that 5.4% (20/370) were penicillin-resistant, non-PPNG strains, of which 100%, 90%, and 45% were also resistant to tetracycline, cefoxitin, and erythromycin, respectively. No resistance to spectinomycin or ceftriaxone was demonstrated, although there was an association between minimum inhibitor concentrations (MICs) of penicillin of greater than or equal to 1.0 microgram/ml and increased MICs of ceftriaxone. The overall incidence of penicillin resistant isolates, including PPNG, was 14.1% (52/370). Of the 20 penicillin-resistant, non-PPNG strains, all were also resistant to tetracycline, and another 21 exhibited tetracycline resistance but were sensitive to penicillin. The in-vitro data suggested that: (1) neither penicillin, tetracycline, nor cefoxitin were acceptable drugs for routine treatment of gonorrhea in our population during the study period; (2) spectinomycin and ceftriaxone continue to demonstrate adequate in-vitro activity against N. gonorrhoeae despite increasing in-vitro resistance to penicillin; and (3) non-plasmid-mediated resistance to penicillin may predict future resistance to ceftriaxone.
对淋病奈瑟菌分离株进行了研究,以确定其抗菌药敏模式及可能的化疗意义。在370株连续分离株中,32株(8.7%)为产青霉素酶淋病奈瑟菌(PPNG)。其余338株进行了纸片扩散试验,对青霉素、四环素或壮观霉素明显耐药的菌株通过琼脂稀释法进行检测。稀释试验表明,5.4%(20/370)为耐青霉素的非PPNG菌株,其中分别有100%、90%和45%也对四环素、头孢西丁和红霉素耐药。虽未发现对壮观霉素或头孢曲松耐药,但青霉素最低抑菌浓度(MIC)大于或等于1.0微克/毫升与头孢曲松MIC升高之间存在关联。包括PPNG在内的耐青霉素分离株的总体发生率为14.1%(52/370)。在20株耐青霉素的非PPNG菌株中,全部也对四环素耐药,另外21株表现出四环素耐药但对青霉素敏感。体外数据表明:(1)在研究期间,青霉素、四环素和头孢西丁都不是我国人群淋病常规治疗的可接受药物;(2)尽管对青霉素的体外耐药性增加,但壮观霉素和头孢曲松对淋病奈瑟菌仍继续表现出足够的体外活性;(3)非质粒介导的青霉素耐药可能预示着未来对头孢曲松的耐药。